Allogeneic SCT in elderly MDS patients
| Reference . | N . | Median age, y (range) . | Conditioning . | Age, y . | NRM, % (y) . | Relapse, % (y) . | DFS, % (y) . | OS, % (y) . |
|---|---|---|---|---|---|---|---|---|
| Lim et al,17 EBMT (2010) | 1333 | 56 (50-74) | RIC: 833 (62%) | — | 36 (44) | 36 (44) | — | 31 (4) |
| 34% > 60 | MA: 500 (38%) | — | 36 (50-60) | 32 (50-60); P = .02 | — | 34 (50-60) | ||
| — | — | — | 39 (> 60) | 41 (> 60); P = .02 | — | 27 (> 60) | ||
| McClune et al,18 * CIBMTR (2010) | 1080 | MDS: 40-78 | 40-54 | 25 (2) | 33 (2) | 42 (2) | 44 (2) | |
| MDS: n = 535 | 10% > 65 | Only RIC or NMA (2 Gy TBI) | 55-59 | 22 (2) | 34 (2) | 43 (2) | 50 (2) | |
| AML 1 CR: n = 545 | AML: 40-79 | 60-64 | 32 (2) | 37 (2) | 31 (2) | 34 (2) | ||
| 12% > 65 | ≥ 65 | 34 (2) | 33 (2) | 34 (2) | 36 (2) |
| Reference . | N . | Median age, y (range) . | Conditioning . | Age, y . | NRM, % (y) . | Relapse, % (y) . | DFS, % (y) . | OS, % (y) . |
|---|---|---|---|---|---|---|---|---|
| Lim et al,17 EBMT (2010) | 1333 | 56 (50-74) | RIC: 833 (62%) | — | 36 (44) | 36 (44) | — | 31 (4) |
| 34% > 60 | MA: 500 (38%) | — | 36 (50-60) | 32 (50-60); P = .02 | — | 34 (50-60) | ||
| — | — | — | 39 (> 60) | 41 (> 60); P = .02 | — | 27 (> 60) | ||
| McClune et al,18 * CIBMTR (2010) | 1080 | MDS: 40-78 | 40-54 | 25 (2) | 33 (2) | 42 (2) | 44 (2) | |
| MDS: n = 535 | 10% > 65 | Only RIC or NMA (2 Gy TBI) | 55-59 | 22 (2) | 34 (2) | 43 (2) | 50 (2) | |
| AML 1 CR: n = 545 | AML: 40-79 | 60-64 | 32 (2) | 37 (2) | 31 (2) | 34 (2) | ||
| 12% > 65 | ≥ 65 | 34 (2) | 33 (2) | 34 (2) | 36 (2) |
— indicates not applicable; MA, myeloablative; NMA, nonmyeloablative; and TBI, total body irradiation.
This study also includes AML patients.